Pharmaceuticals News and Research

RSS

BC Cancer Agency second prestigious Vancouver institution to install MILabs Molecular Imaging System

MILabs is pleased to announce that the BC Cancer Agency, located in Vancouver, British Columbia will install a MILabs U‐SPECT/CT system to expand their current molecular oncology imaging and research capabilities. The U‐SPECT/CT is able to deliver high resolution, sensitivity and scanning speed contributing to outstanding quantification results and the ability to detect heterogeneous molecular processes in tumors.

12 Oct 2012

Brown University, UCI researchers create Drosophila fruit fly model of epilepsy

In a newly reported set of experiments that show the value of a particularly precise but difficult genetic engineering technique, researchers at Brown University and the University of California-Irvine have created a Drosophila fruit fly model of epilepsy to discern the mechanism by which temperature-dependent seizures happen.

12 Oct 2012

Ferozsons Laboratories, BioGaia to sell probiotic drops and tablets in Pakistan

Today BioGaia has signed an agreement with Ferozsons Laboratories Limited, for the exclusive rights to sell BioGaia's probiotic drops and tablets in Pakistan. The products will be sold under the BioGaia brand and launch is planned to 2013.

12 Oct 2012

Financial Times features special report on NTDs

The Financial Times has published a special report on neglected tropical diseases (NTDs) featuring 10 articles examining issues including prevention, research, and treatment.

12 Oct 2012

NYSCF conference to discuss latest advances in stem cell research

Leaders in translational stem cell research from across the country and around the world will present findings on how advances in stem cell science lead to better treatments and cures to disease and injury at The New York Stem Cell Foundation's Seventh Annual Translational Stem Cell Research Conference, held at The Rockefeller University in Manhattan on October 10-11.

11 Oct 2012

Catalent licenses NJIT’s taste-making technology to mask unpleasant and bitter medicines

Following a successful research collaboration with NJIT, Catalent Pharma Solutions of Somerset has announced that it has exclusively licensed innovative taste-making technology developed by NJIT Distinguished Professor Rajesh Dav-, who was the principal investigator of a research project funded by Catalent. The technology will mask the most challenging, unpleasant and bitter tasting pharmaceutical active ingredients.

11 Oct 2012

Older adults do not tend to adhere to their prescribed drugs after heart attack

Older adults who have had a heart attack don't tend to adhere to their prescribed drugs according to a new study of Medicare beneficiaries by the University of Maryland School of Pharmacy.

11 Oct 2012

Researchers develop interference therapies to knock down gene that drives MCL

Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, this disease is devastating, and new therapies are sorely needed.

From Integrated DNA Technologies 11 Oct 2012

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

Leading scientists have selected the first drugs to be evaluated in a worldwide clinical study to determine whether they can prevent Alzheimer's disease.

11 Oct 2012

New drug candidate improves cognitive function of rats with Alzheimer's-like mental impairment

Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer's-like mental impairment.

11 Oct 2012

Keynote speaker on reimbursement for new medicines

Delegates at the largest annual biotech industry gathering in the Asia-Pacific will hear about delays to new medical treatments because of the slow processing of government funding approvals. In many countries, governments pay at least part of the cost of medicines and treatments. However, there is growing concern that delays in funding decisions could mean fewer new medicines are developed in the future.

10 Oct 2012

IspH protein accepts two completely different classes of molecules as partners

The iron-sulfur protein IspH plays a central role in the terpene metabolism of several pathogens. The mechanism of the reaction provides an approach for developing new antibiotics, particularly against malaria and tuberculosis. While researching this enzyme, biochemists at the Technische Universitat Munchen discovered a previously unknown reaction: IspH accepts two completely different classes of molecules as partners.

10 Oct 2012

GSK, Aeras to advance clinical development of TB vaccine

Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E adjuvant.

10 Oct 2012

QRxPharma, Paladin execute licensing agreement for MOXDUO

QRxPharma Limited announced today execution of a licensing agreement with Paladin Labs Inc. for the Canadian commercialisation rights to MOXDUO, a patented, immediate release formulation of morphine and oxycodone.

10 Oct 2012

RMND1 gene mutations responsible for severe neurodegenerative disorders

Scientists at the Montreal Neurological Institute and Hospital - The Neuro, McGill University working with a team at Oxford University have uncovered the genetic defect underlying a group of rare genetic disorders.

10 Oct 2012

AFPE, AAPS enter new strategic alliance to advance pharmaceutical science education

The American Association of Pharmaceutical Scientists (AAPS) and the American Foundation for Pharmaceutical Education (AFPE) have entered into an exciting new strategic alliance to advance support for pharmaceutical science education.

10 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012